Biotika a.s.
BBSSE:1BSL01AE17.00
EUR
0.00
(0.00%)
Biotika a.s.
BSSE:1BSL01AE
(Bratislava Stock Exchange)
Recent
price
17.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biotika a.s. is a Slovakia-based biotechnology and pharmaceutical manufacturing company specializing in the development, fermentation-based production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage pharmaceuticals for human and veterinary applications, and animal nutrition products. The company operates through several core business segments, offering products and services that include active pharmaceutical ingredients such as Penicillin V Potassium, Penicillin G Potassium, Penicillin G Procaine, Polymyxin B Sulfate, Gramicidin S Hydrochloride, and Salinomycin; human and veterinary pharmaceutical preparations, comprising antibiotic formulations, hormonal therapies, injectable vitamin and mineral preparations, and therapeutic analgesics; animal health and agricultural products, including medicated feed premixes, nutritional feed supplements, and disinfectant solutions; and custom contract development and manufacturing organization (CDMO) services encompassing large-scale microbial fermentation, downstream extraction and isolation, chemical synthesis, formulation development, quality control testing, and regulatory documentation adhering to European Union Good Manufacturing Practice (EU GMP) standards. Founded in 1953 and headquartered in Slovenská Ľupča, Slovakia, Biotika a.s. serves pharmaceutical corporations, healthcare providers, and agricultural distributors across domestic and international markets, exporting its products throughout the European Union, North America, and Asia. In recent operational and strategic developments, Biotika a.s. has initiated an industrial expansion program to incorporate the production of anthranilic acid into its manufacturing portfolio, leveraging existing fermentation and purification facilities alongside newly constructed production units in Slovenská Ľupča to broaden its biochemical offering. Additionally, the company secured regulatory approval for Class 1 contained use of genetically modified organisms (GMOs) to support advanced biotechnological processes, while executing strategic operational optimizations and modernizing manufacturing infrastructure to strengthen its global competitiveness.